2020, Número S1
<< Anterior Siguiente >>
Rev Mex Traspl 2020; 9 (S1)
Obesidad y síndrome metabólico (excluyendo diabetes e hipertensión) en donante y receptor
Arreola-Guerra JM
Idioma: Español
Referencias bibliográficas: 25
Paginas: 104-106
Archivo PDF: 190.34 Kb.
FRAGMENTO
El sobrepeso y la obesidad en el mundo han aumentado considerablemente su prevalencia en las últimas décadas. Con base en el último reporte de la Organización para la Cooperación y Desarrollo Económico (OCDE) México se encuentra en el segundo lugar a nivel mundial, con 72.5% de sobrepeso en mayores de 15 años. La asociación entre obesidad y enfermedad renal crónica y mortalidad se ha reportado consistentemente. En los donadores renales el riesgo de mortalidad o enfermedad renal crónica es mayor en específico en quienes presentan obesidad. Las recomendaciones de práctica clínica a nivel mundial sólo establecen que en los pacientes con IMC mayor de 30 kg/m
2 la decisión de donación debe ser individualizada basada en la demografía y otros riesgos de salud.
REFERENCIAS (EN ESTE ARTÍCULO)
GBD 2015 Obesity Collaborators, Afshin A, Forouzanfar MH et al. Health effects of overweight and obesity in 195 countries over 25 years. N Engl J Med. 2017; 377 (1): 13-27.
OECD. Overweight or obese population (indicator). 2019 [Accessed on 16 June 2019] doi: 10.1787/86583552-en
Yarnoff BO, Hoerger TJ, Shrestha SS et al. Modeling the impact of obesity on the lifetime risk of chronic kidney disease in the United States using updated estimates of GFR progression from the CRIC study. PLoS One. 2018; 13 (10): e0205530.
Singh GM, Danaei G, Farzadfar F et al. The age-specific quantitative effects of metabolic risk factors on cardiovascular diseases and diabetes: a pooled analysis. PLoS One. 2013; 8 (7): e65174.
Emerging Risk Factors Collaboration, Wormser D, Kaptoge S et al. Separate and combined associations of body-mass index and abdominal adiposity with cardiovascular disease: collaborative analysis of 58 prospective studies. Lancet. 2011; 377: 1085-1095.
Grams ME, Sang Y, Levey AS et al. Kidney-failure risk projection for the living kidney-donor candidate. N Engl J Med. 2016; 374: 411e421.
Locke JE, Reed RD, Massie A et al. Obesity increases the risk of end-stage renal disease among living kidney donors. Kidney Int. 2017; 91: 699e703.
Locke JE, Reed RD, Massie AB et al. Obesity and long-term mortality risk among living kidney donors. Surgery. 2019 May 6. pii: S0039-6060(19)30167-9.
Lentine KL, Kasiske BL, Levey AS et al. KDIGO clinical practice guidelines on the evaluation and care of living kidney donors. Transplantation. 2017; 101 (Suppl 1): S1-S109.
Rojas R, Aguilar-Salinas CA et al. Metabolic syndrome in Mexican adults: results from the National Health and nutrition survey 2006. Salud Publica Mex. 2010; 52 (Suppl 1): S11-S18.
Chen J, Muntner P, Hamm LL et al. The metabolic syndrome and chronic kidney disease in U.S. adults. Ann Intern Med. 2004; 140: 210-219.
Zhang L, Zuo L, Wang F et al. Metabolic syndrome and chronic kidney disease in a Chinese population aged 40 years and older. Mayo Clin Proc. 2007; 82 (7): 822-827.
Kurella M, Lo JC, Chertow GM. Metabolic syndrome and the risk for chronic kidney disease among nondiabetic adults. J Am Soc Nephrol. 2005; 16 (7): 2134-2140.
Hanson RL, Imperatore G, Bennett PH, Knowler WC. Components of the “metabolic syndrome” and incidence of type 2 diabetes. Diabetes. 2002; 51 (10): 3120-3127.
Resnick HE, Jones K, Ruotolo G et al. Insulin resistance, the metabolic syndrome, and risk of incident cardiovascular disease in nondiabetic American Indians: the Strong Heart Study. Diabetes Care. 2003; 26 (3): 861-867.
Klein BE, Klein R, Lee KE. Components of the metabolic syndrome and risk of cardiovascular disease and diabetes in Beaver Dam. Diabetes Care. 2002; 25 (10): 1790-1794.
Sattar N, Gaw A, Scherbakova O et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation. 2003; 108 (4): 414-419.
Sattar N, McConnachie A, Shaper AG et al. Can metabolic syndrome usefully predict cardiovascular disease and diabetes? Outcome data from two prospective studies. Lancet. 2008; 371 (9628): 1927-1935.
Arellano-Campos O, Gómez-Velasco DV et al. Development and validation of a predictive model for incident type 2 diabetes mellitus in middle-aged Mexican adults: the metabolic syndrome cohort. BMC Endocr Disord. 2019; 19 (1): 41.
Harhay MN, Ranganna K, Boyle SM et al. Association between weight loss before deceased donor kidney transplantation and posttransplantation outcomes. Am J Kidney Dis. 2019 May 16. pii: S0272-6386(19)30666-3.
Gill JS, Lan J, Dong J et al. The survival benefit of kidney transplantation in obese patients. Am J Transplant. 2013; 13: 2083-2090.
Krishnan N, Higgins R, Short A et al. Kidney Transplantation Significantly improves patient and graft survival irrespective of BMI: a cohort study. Am J Transplant. 2015; 15: 2378-2386.
Sood A, Hakim DN, Hakim NS. Consequences of recipient obesity on postoperative outcomes in a renal transplant: a systematic review and meta-analysis. Exp Clin Transplant. 2016; 14 (2): 121-128.
Johnson DW, Isbel NM, Brown AM, Kay TD, Franzen K, Hawley CM et al. The effect on obesity on renal transplant outcomes. Clin Transplant. 2002; 74: 675-681.
Johnson CP, Kuhn EM, Hariharan S, Hartz AJ, Roza AM, Adams MB. Pre-transplant identification of risk factors that adversely affect length of stay and charges for renal transplantation. Clin Transplant. 1999; 13: 168-175.